Rousseau C, Le Thiec M, Ferrer L, et al. - One hundred thirty hormone-naive patients were recruited in a prospective study by the researchers in order to examine the influence of ⁶⁸Ga-PSMA-11 PET-CT on the treatment plan and therapeutic response received for patients with prostate cancer presenting a recurrence with a low rising prostate-specific antigen (PSA). Data analysis for the first 52 involved patients had been finished. In 38/52 patients ⁶⁸Ga-PSMA-11–positive lesions were discovered. Ninety-four lesions were recognized, ie, 53, 24, 12 of 94 in lymph nodes, bone, and into the prostate bed, respectively. Between 0.25 to ≤ 0.69  ng/mL and 0.70  ng/mL, respectively, detection rates were 58%, 81%, and 82% for serum PSA levels lower than 0.25 ng/mL. Therapeutic management altered in 38/52 patients as a result of the PSMA PET-CT. Patients had undetectable serum PSA levels following treatment guided by ⁶⁸Ga-PSMA-11 PET-CT results in 10/52 cases and with a PSA reduction of over 60% in 18/52 patients. Thus, whilst a very low PSA level was demonstrated, preliminary results of the ⁶⁸Ga-PSMA PET-CT study exhibited recurrence localization in more than half of the patients and this had a major clinical impression, as it led to treatment variation in more than half of the patients and a notable reduction in PSA levels in a third of patients.